
|Videos|March 15, 2011
Dr. Langmuir on Vandetanib in Medullary Thyroid Cancer
Author(s)Peter Langmuir, MD
Advertisement
Peter Langmuir, MD, Executive Director, Medical Science AstraZeneca on Vandetanib in Medullary Thyroid Cancer
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
5






































































